Sorry, you need to enable JavaScript to visit this website.

RELPAX®( eletriptan) Has the use of RELPAX® been associated with rebound headache?

Has the use of RELPAX® been associated with rebound headache?

Overuse of all triptans has been reported primarily in patients with chronic daily headache.1

The diagnostic criteria for triptan-overuse headache according to the International Headache Society (IHS), which can accessed at www.ihs-headache.org are as follows:

  • Headache present on ≥15 days/month, which developed or markedly worsened during medication overuse and which resolves or reverts to its previous pattern within 2 months after discontinuation of overused medication.2
  • Triptan intake (any formulation) on ≥10 days/month on a regular basis for > 3 months.2

 

Reference

  1. Relpax®(eletriptan hydrobromide) Product Information
  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33(9) 629–808.  www.ihs-headache.org/ichd-guidelines.

Tips and Tricks

Searching Tips
For more accurate search results, please ensure you enter at least two specific keywords
Haven't found what you are looking for?
Try entering additional or different clinical terms to refine your search. Or you can submit an enquiry online via the Send Medical Enquiry tab or contact Pfizer’s Medical Information Service on 1800 675 229.
Product Information
For a full list of Product Information documents, click on the Product Information tab.
Want to provide some feedback?
Complete the Pfizer Medical Information Website Survey to answer a few questions about your experience and satisfaction with the site.

Contact Pfizer Medical Information

Speak live with a Pfizer Medical Information professional
1800 675 229
Monday to Friday 9am – 5pm EST